Nasopharyngeal carcinoma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1: The pathological type is undifferentiated non-keratinizing carcinoma or adenocarcinoma (according to the World Health Organization, WHO's pathological classification). 2: Imaging examinations include nasopharyngeal MRI or CT and whole-body PET/CT to confirm the presence of the accessory parotid gland. 3: Patients will undergo curative dose radiotherapy for nasopharyngeal cancer. 4: Staging is classified as I-IVA (according to the 8th edition of the American Joint Committee on Cancer (AJCC), Table 6), with no evidence of distant metastasis. 5: Age ranges from 18 to 60 years. 6: Patients must be informed of the basic content of the study and provide signed informed consent.
Exclusion criteria
Exclusion criteria: 1: A history of radiotherapy for head and neck tumors, with the exclusion of radiotherapy for other sites. 2: Uncertainty regarding the presence or location of the accessory parotid gland. 3: Women who are pregnant or breastfeeding (for women of childbearing age, pregnancy tests should be considered; effective contraception should be emphasized during treatment). 4: Presence of other serious illnesses that may pose significant risks or affect compliance with the trial. For example: unstable cardiac conditions requiring treatment, renal disease, chronic hepatitis, poorly controlled diabetes (fasting blood glucose > 1.5×ULN), and mental disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of >= Grade II xerostomia; | — |
Countries
China
Contacts
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University